Cargando…

Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients

The aim of this study was to explore the role of combined pretreatment serum carbohydrate antigen 19-9 (CA19-9) and neutrophil-to-lymphocyte ratio (NLR) as potential prognostic factors in metastatic pancreatic cancer patients. We investigated pretreatment serum CA19-9 and NLR in 59 metastatic pancre...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Jian-Yuan, Chen, Ming-Qiu, Guo, Jing-Hua, Lian, Shi-Feng, Xu, Ben-Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794383/
https://www.ncbi.nlm.nih.gov/pubmed/29369199
http://dx.doi.org/10.1097/MD.0000000000009707
_version_ 1783297116071788544
author Song, Jian-Yuan
Chen, Ming-Qiu
Guo, Jing-Hua
Lian, Shi-Feng
Xu, Ben-Hua
author_facet Song, Jian-Yuan
Chen, Ming-Qiu
Guo, Jing-Hua
Lian, Shi-Feng
Xu, Ben-Hua
author_sort Song, Jian-Yuan
collection PubMed
description The aim of this study was to explore the role of combined pretreatment serum carbohydrate antigen 19-9 (CA19-9) and neutrophil-to-lymphocyte ratio (NLR) as potential prognostic factors in metastatic pancreatic cancer patients. We investigated pretreatment serum CA19-9 and NLR in 59 metastatic pancreatic cancer patients, determined the patients’ thresholds by receiver operating characteristic curve analysis, and assessed their prognostic values by Kaplan–Meier curve and Cox regression models. Results of multivariate analysis showed high CA19-9, high NLR, and high score (the scoring system of CA19-9 and NLR) were significantly correlated with overall survival. Area under the curve of the scoring system was higher than that of CA19-9 or NLR. Combined pretreatment serum CA19-9 and NLR is a better prognostic biomarker of metastatic pancreatic cancer patients than CA19-9 or NLR alone.
format Online
Article
Text
id pubmed-5794383
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-57943832018-02-07 Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients Song, Jian-Yuan Chen, Ming-Qiu Guo, Jing-Hua Lian, Shi-Feng Xu, Ben-Hua Medicine (Baltimore) 5700 The aim of this study was to explore the role of combined pretreatment serum carbohydrate antigen 19-9 (CA19-9) and neutrophil-to-lymphocyte ratio (NLR) as potential prognostic factors in metastatic pancreatic cancer patients. We investigated pretreatment serum CA19-9 and NLR in 59 metastatic pancreatic cancer patients, determined the patients’ thresholds by receiver operating characteristic curve analysis, and assessed their prognostic values by Kaplan–Meier curve and Cox regression models. Results of multivariate analysis showed high CA19-9, high NLR, and high score (the scoring system of CA19-9 and NLR) were significantly correlated with overall survival. Area under the curve of the scoring system was higher than that of CA19-9 or NLR. Combined pretreatment serum CA19-9 and NLR is a better prognostic biomarker of metastatic pancreatic cancer patients than CA19-9 or NLR alone. Wolters Kluwer Health 2018-01-26 /pmc/articles/PMC5794383/ /pubmed/29369199 http://dx.doi.org/10.1097/MD.0000000000009707 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0
spellingShingle 5700
Song, Jian-Yuan
Chen, Ming-Qiu
Guo, Jing-Hua
Lian, Shi-Feng
Xu, Ben-Hua
Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients
title Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients
title_full Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients
title_fullStr Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients
title_full_unstemmed Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients
title_short Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients
title_sort combined pretreatment serum ca19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794383/
https://www.ncbi.nlm.nih.gov/pubmed/29369199
http://dx.doi.org/10.1097/MD.0000000000009707
work_keys_str_mv AT songjianyuan combinedpretreatmentserumca199andneutrophiltolymphocyteratioasapotentialprognosticfactorinmetastaticpancreaticcancerpatients
AT chenmingqiu combinedpretreatmentserumca199andneutrophiltolymphocyteratioasapotentialprognosticfactorinmetastaticpancreaticcancerpatients
AT guojinghua combinedpretreatmentserumca199andneutrophiltolymphocyteratioasapotentialprognosticfactorinmetastaticpancreaticcancerpatients
AT lianshifeng combinedpretreatmentserumca199andneutrophiltolymphocyteratioasapotentialprognosticfactorinmetastaticpancreaticcancerpatients
AT xubenhua combinedpretreatmentserumca199andneutrophiltolymphocyteratioasapotentialprognosticfactorinmetastaticpancreaticcancerpatients